Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.

BE Shaw; JF Apperley; NH Russell; Charles Craddock; E Liakopoulou; MN Potter; R Wynn; B Gibson; RM Pearce; K Kirkland; Jou Lee; JA Madrigal; G Cook; JL Byrne

doi:10.1111/j.1365-2141.2011.08615.x

Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.

BE Shaw, JF Apperley, NH Russell, Charles Craddock, E Liakopoulou, MN Potter, R Wynn, B Gibson, RM Pearce, K Kirkland, Jou Lee, JA Madrigal, G Cook, JL Byrne

Research output: Contribution to journal › Article

15 Citations (Scopus)

Abstract

There is little information published comparing peripheral blood stem cells (PBSC) with bone marrow (BM) as the stem cell source in the long-term outcome in recipients of T-cell depleted (TCD) unrelated donor (UD) transplants. We present retrospective outcome data on 306 recipients of myeloablative, human leucocyte antigen-matched UD allografts using pre-transplant in-vivo Alemtuzumab. Transplants were performed between 2000 and 2007 for chronic myeloid leukaemia in first chronic phase and acute leukaemia in first or second complete remission; 184 patients received BM and 122 PBSC. The median age was 28·9 years (

Original language	English
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/j.1365-2141.2011.08615.x
Publication status	Published - 8 Mar 2011

Access to Document

10.1111/j.1365-2141.2011.08615.x

Fingerprint

Dive into the research topics of 'Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.'. Together they form a unique fingerprint.

Cite this

Shaw, BE., Apperley, JF., Russell, NH., Craddock, C., Liakopoulou, E., Potter, MN., Wynn, R., Gibson, B., Pearce, RM., Kirkland, K., Lee, J., Madrigal, JA., Cook, G., & Byrne, JL. (2011). Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2011.08615.x

@article{e11ce2a50dc1485484f8c9e8bff082d0,

title = "Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.",

abstract = "There is little information published comparing peripheral blood stem cells (PBSC) with bone marrow (BM) as the stem cell source in the long-term outcome in recipients of T-cell depleted (TCD) unrelated donor (UD) transplants. We present retrospective outcome data on 306 recipients of myeloablative, human leucocyte antigen-matched UD allografts using pre-transplant in-vivo Alemtuzumab. Transplants were performed between 2000 and 2007 for chronic myeloid leukaemia in first chronic phase and acute leukaemia in first or second complete remission; 184 patients received BM and 122 PBSC. The median age was 28·9 years (",

author = "BE Shaw and JF Apperley and NH Russell and Charles Craddock and E Liakopoulou and MN Potter and R Wynn and B Gibson and RM Pearce and K Kirkland and Jou Lee and JA Madrigal and G Cook and JL Byrne",

year = "2011",

month = mar,

day = "8",

doi = "10.1111/j.1365-2141.2011.08615.x",

language = "English",

journal = "British Journal of Haematology",

issn = "1365-2141",

publisher = "Wiley",

}

Shaw, BE, Apperley, JF, Russell, NH, Craddock, C, Liakopoulou, E, Potter, MN, Wynn, R, Gibson, B, Pearce, RM, Kirkland, K, Lee, J, Madrigal, JA, Cook, G & Byrne, JL 2011, 'Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.', British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2011.08615.x

TY - JOUR

T1 - Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.

AU - Shaw, BE

AU - Apperley, JF

AU - Russell, NH

AU - Craddock, Charles

AU - Liakopoulou, E

AU - Potter, MN

AU - Wynn, R

AU - Gibson, B

AU - Pearce, RM

AU - Kirkland, K

AU - Lee, Jou

AU - Madrigal, JA

AU - Cook, G

AU - Byrne, JL

PY - 2011/3/8

Y1 - 2011/3/8

N2 - There is little information published comparing peripheral blood stem cells (PBSC) with bone marrow (BM) as the stem cell source in the long-term outcome in recipients of T-cell depleted (TCD) unrelated donor (UD) transplants. We present retrospective outcome data on 306 recipients of myeloablative, human leucocyte antigen-matched UD allografts using pre-transplant in-vivo Alemtuzumab. Transplants were performed between 2000 and 2007 for chronic myeloid leukaemia in first chronic phase and acute leukaemia in first or second complete remission; 184 patients received BM and 122 PBSC. The median age was 28·9 years (

AB - There is little information published comparing peripheral blood stem cells (PBSC) with bone marrow (BM) as the stem cell source in the long-term outcome in recipients of T-cell depleted (TCD) unrelated donor (UD) transplants. We present retrospective outcome data on 306 recipients of myeloablative, human leucocyte antigen-matched UD allografts using pre-transplant in-vivo Alemtuzumab. Transplants were performed between 2000 and 2007 for chronic myeloid leukaemia in first chronic phase and acute leukaemia in first or second complete remission; 184 patients received BM and 122 PBSC. The median age was 28·9 years (

UR - https://www.scopus.com/pages/publications/79953080775

U2 - 10.1111/j.1365-2141.2011.08615.x

DO - 10.1111/j.1365-2141.2011.08615.x

M3 - Article

C2 - 21382020

SN - 1365-2141

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -